CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030
The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025, at a significant CAGR of 11.2%.
The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines.
“Products dominated the CRISPR market, by offering, in 2024.”
Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services.
Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth.
“The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period.”
The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology.
“Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024.”
Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share.
“North America accounted for the largest share of the CRISPR market in 2024.”
The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)].
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market.
Key Benefits of Buying the Report:
The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market.
The report provides insights into the following pointers:
The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines.
“Products dominated the CRISPR market, by offering, in 2024.”
Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services.
Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth.
“The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period.”
The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology.
“Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024.”
Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share.
“North America accounted for the largest share of the CRISPR market in 2024.”
The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (35%), Europe (30%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Research Coverage:
The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)].
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market.
Key Benefits of Buying the Report:
The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market.
The report provides insights into the following pointers:
- Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases and expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the market.
- Product Development/Innovation: In-depth analysis of emerging technologies in CRISPR, R&D activities, and new product launches in the CRISPR market.
- Market Development: The report provides detailed information about profitable markets and analyzes the market conditions across various regions.
- Market Diversification: Comprehensive information about new products, unexplored regions, recent updates, and investments in the CRISPR market.
- Competitive Assessment: Comprehensive evaluation of market shares, growth strategies, and product & service offerings of leading companies such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Insights From Primary Experts
2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CRISPR MARKET OVERVIEW
4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)
4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for CRISPR-based gene therapies
5.2.1.2 Advancements in CRISPR technology
5.2.1.3 Growing government and private investments and funding for
CRISPR technology
5.2.2 RESTRAINTS
5.2.2.1 Technical challenges associated with CRISPR technology
5.2.3 OPPORTUNITIES
5.2.3.1 Development of new vaccines and treatments for genetic diseases
5.2.3.2 Expanding industrial and agricultural applications of CRISPR
5.2.4 CHALLENGES
5.2.4.1 Regulatory hurdles for CRISPR advancements
5.2.5 TECHNOLOGY ANALYSIS
5.2.5.1 Key technologies
5.2.5.1.1 CRISPR-Cas systems
5.2.5.1.2 gRNA design & optimization
5.2.5.1.3 High-throughput CRISPR screening
5.2.5.2 Complementary technologies
5.2.5.2.1 Synthetic biology
5.2.5.2.2 Single-cell genomics
5.2.5.2.3 Next-generation sequencing
5.2.5.3 Adjacent technologies
5.2.5.3.1 Stem cell engineering
5.2.5.3.2 Synthetic DNA & gene synthesis
5.2.5.3.3 Microfluidics
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
5.8.2 REGULATORY FRAMEWORK
5.8.2.1 North America
5.8.2.1.1 US
5.8.2.1.2 Canada
5.8.2.2 Europe
5.8.2.2.1 Germany
5.8.2.2.2 UK
5.8.2.2.3 France
5.8.2.3 Asia Pacific
5.8.2.3.1 Japan
5.8.2.3.2 China
5.8.2.4 Latin America
5.8.2.4.1 Brazil
5.8.2.5 Middle East & Africa
5.8.2.5.1 GCC Countries
5.8.2.5.2 South Africa
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS,
BY KEY PLAYER, 2022–2024
5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES
5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS,
BY REGION, 2024
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS, 2025–2026
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 CRISPR MARKET: BUYING CRITERIA
5.13 INVESTMENT & FUNDING SCENARIO
5.14 IMPACT OF AI ON CRISPR MARKET
5.15 TRADE ANALYSIS
5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019–2023
5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019–2023
5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET
5.15.3.1 Introduction
5.15.3.2 Key tariff rates
5.15.3.3 Price impact analysis
5.15.3.4 Key Impact on various regions
5.15.3.4.1 US
5.15.3.4.2 Europe
5.15.3.4.3 Asia Pacific
5.15.3.4.4 Rest of the World
5.15.3.5 End-use industry impact
5.15.3.5.1 Pharmaceutical & biotech companies
5.15.3.5.2 Contract research organizations (CROs)
5.15.3.5.3 Academic & research institutes
6 CRISPR MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
6.3 SERVICES
6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET
7 CRISPR PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CRISPR KITS & ENZYMES
7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
7.3 CRISPR LIBRARIES
7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING
TO DRIVE GROWTH
7.4 OTHER PRODUCTS
8 CRISPR PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL
PIPELINE TO PROPEL MARKET
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
8.4 OTHER END USERS
9 CRISPR MARKET, BY SERVICE
9.1 INTRODUCTION
9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
9.1.2 SCREENING & VALIDATION
9.1.2.1 Rapid advancements in CRISPR technology to drive growth
9.2 OTHER SERVICES
10 CRISPR SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
10.4 OTHER END USERS
11 CRISPR MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DRUG DISCOVERY & DEVELOPMENT
11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
11.3 AGRICULTURE
11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
11.4 OTHER APPLICATIONS
12 CRISPR MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth
12.2.3 CANADA
12.2.3.1 Increasing demand for gene-editing technologies to boost growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK OF EUROPE
12.3.2 GERMANY
12.3.2.1 Rapidly increasing biotechnology sector to support growth
12.3.3 UK
12.3.3.1 Significant government investments in genomics research to propel growth
12.3.4 FRANCE
12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth
12.3.5 ITALY
12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth
12.3.6 SPAIN
12.3.6.1 Increasing demand for precision medicine to drive growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Increasing investments in R&D to drive growth
12.4.3 JAPAN
12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
12.4.4 INDIA
12.4.4.1 Increasing prevalence of genetic disorders to support growth
12.4.5 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing adoption of genome technologies to propel growth
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
13.3 REVENUE ANALYSIS, 2020?2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Product footprint
13.5.5.4 Service footprint
13.5.5.5 Application footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
13.6.5.1 Detailed list of key startups/SMEs
13.6.5.2 Competitive benchmarking of key startups/SMEs
13.7 COMPETITIVE SCENARIO
13.7.1 PRODUCT LAUNCHES & APPROVALS
13.7.2 DEALS
13.7.3 EXPANSIONS
13.8 COMPANY VALUATION & FINANCIAL METRICS
13.9 BRAND/PRODUCT COMPARISON
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.1.1 Business overview
14.1.1.2 Products/Services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product/Service launches
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 MERCK KGAA
14.1.2.1 Business overview
14.1.2.2 Products/Services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products/Services offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.3.2 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 GENSCRIPT
14.1.4.1 Business overview
14.1.4.2 Products/Services offered
14.1.4.3 Recent developments
14.1.4.3.1 Product/service approvals/launches
14.1.4.3.2 Deals
14.1.4.3.3 Expansions
14.1.5 REVVITY
14.1.5.1 Business overview
14.1.5.2 Products/Services offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.6 LONZA
14.1.6.1 Business overview
14.1.6.2 Products/Services offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 DANAHER CORPORATION
14.1.7.1 Business overview
14.1.7.2 Products/Services offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.8 TAKARA BIO INC.
14.1.8.1 Business overview
14.1.8.2 Products/Services offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 CREATIVE BIOGENE
14.1.9.1 Business overview
14.1.9.2 Products/Services offered
14.1.9.3 Recent developments
14.1.9.3.1 Product/service approvals/launches
14.1.10 FUJIAN SUNYBIOTECH CO., LTD.
14.1.10.1 Business overview
14.1.10.2 Products/Services offered
14.1.11 EDITCO
14.1.11.1 Business overview
14.1.11.2 Products/Services offered
14.1.11.3 Recent financials
14.1.11.3.1 Deals
14.1.12 CARIBOU BIOSCIENCES, INC.
14.1.12.1 Business overview
14.1.12.2 Products/Services offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 HERA BIOLABS
14.1.13.1 Business overview
14.1.13.2 Products/Services offered
14.1.14 ORIGENE TECHNOLOGIES, INC.
14.1.14.1 Business overview
14.1.14.2 Products/Services offered
14.1.15 CELLECTA, INC.
14.1.15.1 Business overview
14.1.15.2 Products/Services offered
14.2 OTHER PLAYERS
14.2.1 MAMMOTH BIOSCIENCES, INC.
14.2.2 APPLIED STEMCELL
14.2.3 NEW ENGLAND BIOLABS
14.2.4 TOOLGEN, INC.
14.2.5 GENECOPOEIA, INC.
14.2.6 TWIST BIOSCIENCE
14.2.7 SYNTHEGO
14.2.8 EGENESIS
14.2.9 INSCRIPTA, INC.
14.2.10 PRECISION BIOSCIENCES
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Insights From Primary Experts
2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CRISPR MARKET OVERVIEW
4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)
4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for CRISPR-based gene therapies
5.2.1.2 Advancements in CRISPR technology
5.2.1.3 Growing government and private investments and funding for
CRISPR technology
5.2.2 RESTRAINTS
5.2.2.1 Technical challenges associated with CRISPR technology
5.2.3 OPPORTUNITIES
5.2.3.1 Development of new vaccines and treatments for genetic diseases
5.2.3.2 Expanding industrial and agricultural applications of CRISPR
5.2.4 CHALLENGES
5.2.4.1 Regulatory hurdles for CRISPR advancements
5.2.5 TECHNOLOGY ANALYSIS
5.2.5.1 Key technologies
5.2.5.1.1 CRISPR-Cas systems
5.2.5.1.2 gRNA design & optimization
5.2.5.1.3 High-throughput CRISPR screening
5.2.5.2 Complementary technologies
5.2.5.2.1 Synthetic biology
5.2.5.2.2 Single-cell genomics
5.2.5.2.3 Next-generation sequencing
5.2.5.3 Adjacent technologies
5.2.5.3.1 Stem cell engineering
5.2.5.3.2 Synthetic DNA & gene synthesis
5.2.5.3.3 Microfluidics
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
5.8.2 REGULATORY FRAMEWORK
5.8.2.1 North America
5.8.2.1.1 US
5.8.2.1.2 Canada
5.8.2.2 Europe
5.8.2.2.1 Germany
5.8.2.2.2 UK
5.8.2.2.3 France
5.8.2.3 Asia Pacific
5.8.2.3.1 Japan
5.8.2.3.2 China
5.8.2.4 Latin America
5.8.2.4.1 Brazil
5.8.2.5 Middle East & Africa
5.8.2.5.1 GCC Countries
5.8.2.5.2 South Africa
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS,
BY KEY PLAYER, 2022–2024
5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES
5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS,
BY REGION, 2024
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS, 2025–2026
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 CRISPR MARKET: BUYING CRITERIA
5.13 INVESTMENT & FUNDING SCENARIO
5.14 IMPACT OF AI ON CRISPR MARKET
5.15 TRADE ANALYSIS
5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019–2023
5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019–2023
5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET
5.15.3.1 Introduction
5.15.3.2 Key tariff rates
5.15.3.3 Price impact analysis
5.15.3.4 Key Impact on various regions
5.15.3.4.1 US
5.15.3.4.2 Europe
5.15.3.4.3 Asia Pacific
5.15.3.4.4 Rest of the World
5.15.3.5 End-use industry impact
5.15.3.5.1 Pharmaceutical & biotech companies
5.15.3.5.2 Contract research organizations (CROs)
5.15.3.5.3 Academic & research institutes
6 CRISPR MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
6.3 SERVICES
6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET
7 CRISPR PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CRISPR KITS & ENZYMES
7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
7.3 CRISPR LIBRARIES
7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING
TO DRIVE GROWTH
7.4 OTHER PRODUCTS
8 CRISPR PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL
PIPELINE TO PROPEL MARKET
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
8.4 OTHER END USERS
9 CRISPR MARKET, BY SERVICE
9.1 INTRODUCTION
9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
9.1.2 SCREENING & VALIDATION
9.1.2.1 Rapid advancements in CRISPR technology to drive growth
9.2 OTHER SERVICES
10 CRISPR SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
10.4 OTHER END USERS
11 CRISPR MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DRUG DISCOVERY & DEVELOPMENT
11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
11.3 AGRICULTURE
11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
11.4 OTHER APPLICATIONS
12 CRISPR MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth
12.2.3 CANADA
12.2.3.1 Increasing demand for gene-editing technologies to boost growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK OF EUROPE
12.3.2 GERMANY
12.3.2.1 Rapidly increasing biotechnology sector to support growth
12.3.3 UK
12.3.3.1 Significant government investments in genomics research to propel growth
12.3.4 FRANCE
12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth
12.3.5 ITALY
12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth
12.3.6 SPAIN
12.3.6.1 Increasing demand for precision medicine to drive growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Increasing investments in R&D to drive growth
12.4.3 JAPAN
12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
12.4.4 INDIA
12.4.4.1 Increasing prevalence of genetic disorders to support growth
12.4.5 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing adoption of genome technologies to propel growth
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
13.3 REVENUE ANALYSIS, 2020?2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Product footprint
13.5.5.4 Service footprint
13.5.5.5 Application footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
13.6.5.1 Detailed list of key startups/SMEs
13.6.5.2 Competitive benchmarking of key startups/SMEs
13.7 COMPETITIVE SCENARIO
13.7.1 PRODUCT LAUNCHES & APPROVALS
13.7.2 DEALS
13.7.3 EXPANSIONS
13.8 COMPANY VALUATION & FINANCIAL METRICS
13.9 BRAND/PRODUCT COMPARISON
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.1.1 Business overview
14.1.1.2 Products/Services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product/Service launches
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 MERCK KGAA
14.1.2.1 Business overview
14.1.2.2 Products/Services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products/Services offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.3.2 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 GENSCRIPT
14.1.4.1 Business overview
14.1.4.2 Products/Services offered
14.1.4.3 Recent developments
14.1.4.3.1 Product/service approvals/launches
14.1.4.3.2 Deals
14.1.4.3.3 Expansions
14.1.5 REVVITY
14.1.5.1 Business overview
14.1.5.2 Products/Services offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.6 LONZA
14.1.6.1 Business overview
14.1.6.2 Products/Services offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 DANAHER CORPORATION
14.1.7.1 Business overview
14.1.7.2 Products/Services offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.8 TAKARA BIO INC.
14.1.8.1 Business overview
14.1.8.2 Products/Services offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 CREATIVE BIOGENE
14.1.9.1 Business overview
14.1.9.2 Products/Services offered
14.1.9.3 Recent developments
14.1.9.3.1 Product/service approvals/launches
14.1.10 FUJIAN SUNYBIOTECH CO., LTD.
14.1.10.1 Business overview
14.1.10.2 Products/Services offered
14.1.11 EDITCO
14.1.11.1 Business overview
14.1.11.2 Products/Services offered
14.1.11.3 Recent financials
14.1.11.3.1 Deals
14.1.12 CARIBOU BIOSCIENCES, INC.
14.1.12.1 Business overview
14.1.12.2 Products/Services offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 HERA BIOLABS
14.1.13.1 Business overview
14.1.13.2 Products/Services offered
14.1.14 ORIGENE TECHNOLOGIES, INC.
14.1.14.1 Business overview
14.1.14.2 Products/Services offered
14.1.15 CELLECTA, INC.
14.1.15.1 Business overview
14.1.15.2 Products/Services offered
14.2 OTHER PLAYERS
14.2.1 MAMMOTH BIOSCIENCES, INC.
14.2.2 APPLIED STEMCELL
14.2.3 NEW ENGLAND BIOLABS
14.2.4 TOOLGEN, INC.
14.2.5 GENECOPOEIA, INC.
14.2.6 TWIST BIOSCIENCE
14.2.7 SYNTHEGO
14.2.8 EGENESIS
14.2.9 INSCRIPTA, INC.
14.2.10 PRECISION BIOSCIENCES
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
